anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: The management of non-communicable diseases (NCDs) has benefited from telehealth services. As these services which include teleconsultation services and e-prescriptions are relatively new in Malaysia, the data generated provide an unprecedented opportunity to study medication use patterns for the management of NCDs in the country. We analyze e-prescriptions from a local telehealth service to identify medication use patterns and potential areas to optimize medication use in relation to clinical practice guidelines.
METHODS: A cross sectional observational study was conducted by retrieving e-prescription records retrospectively from a telehealth service. 739,482 records from January 2019 to December 2021 were extracted using a designated data collection form. Data cleaning, standardization and data analysis were performed using Python version 3.11. The diagnoses were classified according to the International Classification of Disease 10 (ICD-10), while medications were classified using the Anatomical Therapeutic Chemical (ATC) system. Diagnoses, frequency of use for medication classes and individual medications were analyzed and compared to clinical practice guidelines.
RESULTS: The top five NCD diagnoses utilized by the service were hypertension (37.7%), diabetes mellitus (25.1%), ischemic heart disease (24.3%), asthma (14.4%), and dyslipidemia (11.7%). Medications were prescribed mostly in accordance with guideline recommendations. However, angiotensin receptor blockers (ARBs) were significantly more frequently prescribed compared to angiotensin converting enzyme inhibitors (ACEIs). Several medication classes appeared underutilized, including ACEIs in hypertensive patients with diabetes or ischemic heart disease, sodium glucose cotransporter 2 inhibitors in diabetic patients with ischemic heart disease, and metformin in patients with diabetes.
CONCLUSIONS: Telehealth services are currently being utilized for the management of NCDs. Medication use for the management of NCDs through these services are mostly in accordance with guideline recommendations, but there exist areas that would warrant further investigation to ensure optimal clinical and economic outcomes are achieved.
Following screening procedures, subjects will be randomized at baseline to receive fasudil or matching placebo across all cohorts. 1:1 randomization will be performed.
Isolated fragments of the HFE2A protein able to bind and modulate HFE2A and other proteins, such as hepcidin, involved in the iron metabolism pathway are disclosed, such fragments being of molecular weight of approximately 7 kDa to 43 kDa. Also disclosed are corresponding isolated polynucleotides encoding the fragments of the HFE2A protein. The invention includes derivatives and analogs of the polypeptide fragments of HFE2A, along with compositions of these, that are functionally active, i.e. capable of interacting with the HFE2A, as well as methods of production of the HFE2A cleavage products, derivatives and analogs, e.g. by recombinant means. Methods for identifying modulators of HFE2A, comprising contacting a test compound with HFE2A and determining a change in HFE2A activity due to the compound, are provided. Also taught are methods of diagnosing an animal afflicted with or at risk of developing a disease of iron metabolism comprising determining a change in the level, amount or activity of a fragment of an HFE2A obtained in a sample from said animal relative to the level, amount or activity of a fragment of an HFE2A obtained in a control sample from an unaffected animal, wherein a change identifies said individual as being affect by or at risk of developing a disease of iron metabolism. Methods for treating and/or preventing a disorder in animals comprising administering to an animal afflicted therewith, or at risk of developing said disorder, a therapeutically effective amount of an HFE2A modulator are provided.
Participants received intravenous infusions of placebo once every 4 weeks until Week 12. Following the Week 12 visit, participants who completed Part 1 of the study received open-label 8 mg/kg tocilizumab through Week 208.
The invention discloses a foot bath traditional Chinese medicine for promoting health and treating insomnia of middle-aged and elderly people and a using method thereof. In the invention, the foot-soaking coagulated beads are extracted with pure concentrated protoplasm of traditional Chinese medicines, and the concentrate is essence; small molecule scientific penetration technology, skin is easy to absorb, saffron; has effects in enhancing immunity, lowering blood pressure, reducing blood lipid, relieving physical fatigue, improving anoxia tolerance, removing acne, and relieving constipation. Is helpful for relieving fatigue, relaxing body and mind, and promoting metabolism. Mugwort, mugwort leaf oil; bupleuri radix; has the functions of harmonizing exterior and interior, soothing liver and invigorating yang. Is helpful for coordinating yin and yang, and can prevent common cold and discomfort caused by common cold in arch; patchouli oil; is an important natural spice in the spice industry, has the effects of resisting bacteria and diminishing inflammation, helping people wear shoes for a long time, causing foot stuffiness, beriberi and the like, diminishing inflammation of feet, and achieving the effect of removing beriberi. Lavender extract; has effects in balancing oil secretion, relieving inflammation, killing bacteria, and relieving stress. Is helpful for maintaining beauty and keeping young, soothing nerves and helping sleep.
Postmarketing reports suggest that patients treated with anti-Parkinson medications can experience intense urges to gamble, increased sexual urges, intense urges to spend money uncontrollably, and other intense urges. Patients may be unable to control these urges while taking one or more of the medications that are generally used for the treatment of Parkinson’s disease and that increase central dopaminergic tone, including amantadine hydrochloride. In some cases, although not all, these urges were reported to have stopped when the dose was reduced or the medication was discontinued. Because patients may not recognize these behaviors as abnormal it is important for prescribers to specifically ask patients or their caregivers about the development of new or increased gambling urges, sexual urges, uncontrolled spending or other urges while being treated with amantadine hydrochloride. Physicians should consider dose reduction or stopping the medication if a patient develops such urges while taking amantadine hydrochloride.

Melanoma:

Epidemiological studies have shown that patients with Parkinson’s disease have a higher risk (2- to approximately 6-fold higher) of developing melanoma than the general population. Whether the increased risk observed was due to Parkinson’s disease or other factors, such as drugs used to treat Parkinson’s disease, is unclear.

For the reasons stated above, patients and providers are advised to monitor for melanomas frequently and on a regular basis when using amantadine hydrochloride for any indication. Ideally, periodic skin examinations should be performed by appropriately qualified individuals (e.g., dermatologists).

Other: The dose of amantadine hydrochloride may need careful adjustment in patients with congestive heart failure, peripheral edema, or orthostatic hypotension. Care should be exercised when administering amantadine hydrochloride to patients with a history of recurrent eczematoid rash, or to patients with psychosis or severe psychoneurosis not controlled by chemotherapeutic agents. 

Serious bacterial infections may begin with influenza-like symptoms or may coexist with or occur as complications during the course of influenza. Amantadine hydrochloride has not been shown to prevent such complications.
FIELD: medicine, clinical pharmacology. SUBSTANCE: invention deals with creating a multipurpose preparation which is not of antitumor action itself, but, also, efficiently decreases side effects of different antitumor products, both chemotherapeutical and radiological ones, and development of the method based upon application of such a preparation. Result is achieved due to peroral intake of squalene preactivated either by thermal treatment or UV-, IR-radiation or impact of active oxygen form. Preparation should be used in efficient quantity, optimally - at the dosage of 0.3 ml/kg body weight in case of gastric, intestinal, pulmonary cancers, carcinomas of endo- and exoglands and at leucosis. EFFECT: broadened number of antitumor products. 9 cl, 4 ex, 1 tbl
The present invention relates to a fusion protein comprising a GDF15 variant having increased physiological activity and in vivo stability, and a pharmaceutical composition comprising the same. The GDF15 variant or long-acting GDF15 fusion protein according to the present invention has superior in vitro efficacy, GDF15 receptor binding affinity and weight loss effect compared to the existing GDF15 variant. Accordingly, the pharmaceutical composition comprising the GDF15 variant, long-acting GDF15 fusion protein or fusion protein dimer of the present invention as an active ingredient can be usefully used as a therapeutic agent for metabolic diseases or obesity through appetite suppression. Furthermore, the pharmaceutical composition comprising a GDF15 variant, a long-acting GDF15 fusion protein or a fusion protein dimer as an active ingredient can be used in combination therapy with chemical drugs and other therapeutic agents for metabolic diseases, etc., and be usefully used as a combination therapy with existing therapeutic agents for metabolic diseases and obesity. In order to acheive the purpose, the present invention provides the GDF15 variant represented by following Formula 1. Formula 1 represents an N-terminus expansion domain - a core domain.
Wait-List control group will participate in visits every 4 weeks for data collection and periodic phone calls for monitoring. They will be offered the exercise training intervention option at conclusion.
Processes for increasing a viricidal activity of a fiber substrate. The fiber substrate is provided. The fiber substrate may comprise acidic functional groups and may be acid leached to provide additional acidic groups. Metal ions may thereafter be exchanged with a proton from the acidic functional groups. A divalent metal is introduced to the fiber substrate. An antiviral metal is introduced and deposited onto the fiber substrate by galvanic displacement. Subsequently, a further antiviral metal is introduced and deposited on the fiber substrate by an electroless process. The treated fiber substrate is washed and dried. The deposition of antiviral metals onto the fiber substrate to form a treated fiber substrate may occur before or after the fiber substrate is incorporated into a filter media in a wet-laid paper making process.
Up to 4 cohorts of participants with R/R B-ALL will be enrolled to the preliminary recommended phase 2 dose (RP2D) and schedule determined from dose escalation phase. Each cohort will aim to further assess safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy.
<P>PROBLEM TO BE SOLVED: To provide a moisture-retaining plant extract retaining moisture-retaining effect for a long time and an external preparation, a cosmetic, a bathing agent and a detergent composition each containing the extract.  <P>SOLUTION: The moisture-retaining plant extract comprises an extract of a mixture of Cinnamomum cassia Blume with Paeonia lactiflora Pallas and Prunus persica Batsch var. davidiana Maximowicz. The cosmetic, the bathing agent and the detergent composition each comprises the extract. A product obtained by decocting the above crude medicines in prescribed proportions is called Hainousan (pus-discharging medicine) in Chinese medicine formulation and the product is the same composition as a medicine which is effective for purulent skin diseases, etc., by oral administration. The extract of the mixture of those crude medicines comprises moisture-retaining plant ingredients retaining moisture-retaining effect for a long time and the extract is effective for prophylaxis, alleviation or amelioration of dryness of the skin, rough skin, cracks, chaps, dandruff, itching, inflammatory disease by external use and also effective for dryness of the hair, looseness, split hair, broken hair, impartation, etc., of gloss to the hair.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Fibrosing colonopathy, including colonic stricture formation, has been reported with postmarketing use of PROCYSBI in pediatric and young adult patients with nephropathic cystinosis. Some of these patients had been treated with PROCYSBI for prolonged periods of time. Reported symptoms include: abdominal pain, vomiting, bloody or persistent diarrhea, and fecal incontinence. Evaluate patients with severe, persistent, and/or worsening abdominal symptoms for fibrosing colonopathy. If the diagnosis is confirmed, permanently discontinue PROCYSBI and switch to immediate-release cysteamine bitartrate capsules. An association between methacrylic acid-ethyl acrylate copolymer (an inactive ingredient in PROCYSBI) and fibrosing colonopathy cannot be ruled out.
Background and Objectives: This study explored how nefopam, a non-opioid analgesic in a multimodal regimen, impacts postoperative pain, opioid use, and recovery quality in single-port robot-assisted laparoscopic cholecystectomy (RALC) patients with a parietal pain block, addressing challenges in postoperative pain management. Materials and Methods: Forty patients scheduled for elective single-port RALC were enrolled and randomized to receive either nefopam or normal saline intravenously. Parietal pain relief was provided through a rectus sheath block (RSB). Postoperative pain was assessed using a numeric rating scale (NRS) in the right upper quadrant (RUQ) of the abdomen, at the umbilicus, and at the shoulder. Opioid consumption and recovery quality, measured using the QoR-15K questionnaire, were also recorded. Results: The 40 patients had a mean age of 48.3 years and an average body mass index (BMI) of 26.2 kg/m2. There were no significant differences in the pre- or intraoperative variables between groups. Patients receiving nefopam reported significantly lower RUQ pain scores compared to the controls, while the umbilicus and shoulder pain scores were similar. Rescue fentanyl requirements were lower in the nefopam group in both the PACU and ward. The QoR-15K questionnaire scores for nausea and vomiting were better in the nefopam group, but the overall recovery quality scores were comparable between the groups. Conclusions: Nefopam reduces RUQ pain and opioid use post-single-port RALC with a parietal pain block without markedly boosting RSB's effect on umbilicus or shoulder pain. It may also better manage postoperative nausea and vomiting, underscoring its role in analgesia strategies for this surgery.
Approximately 350,000 end-stage renal disease (ESRD) patients in the United States utilized over $17.9 billion Medicare dollars in 1999. The ESRD population and cost is projected to double by 2010. ESRD patients have a mean of 5 comorbidities per patient and are prescribed a median of eight medications. The average monthly medication cost per patient is approximately $1,200.00. For every dollar spent on medication an additional $1.77 is spent on drug-related problems (DRPs). Dialysis patients are at high risk for DRPs. It is unknown if continued pharmacist intervention in hemodialysis patients will improve patient care, reduce medication utilization and cost, and prevent hospitalization as seen in other populations. The purpose of this study is to investigate the impact of continued pharmacist intervention in ambulatory hemodialysis patients.
The COVID-19 pandemic's prolonged extension may have had a long-term negative impact on weight and metabolic parameters associated with the effectiveness of bariatric surgery. The aim of this study was to assess the impact of the COVID-19 pandemic on cardiometabolic risk markers and weight outcomes of post-bariatric patients. This is a longitudinal study carried out with patients who underwent bariatric surgery before the COVID-19 pandemic. Anthropometric, lipid, glycemic profile, blood pressure, eating behavior and physical activity parameters obtained through face-to-face consultations from 2019 to 2022 were evaluated. An increase in BMI (p = 0.001), percentage of weight gain (p < 0.001), postoperative weight regain rate (p = 0.002), fasting blood glucose (p < 0.001), and glycosylated hemoglobin (p < 0.001) was identified. There were reductions in the percentages of excess weight loss (p = 0.001) and physically active individuals (p = 0.016). These changes were only triggered after the pandemic years. Uncontrolled eating, emotional eating, and physical inactivity were identified as risk factors for weight gain during the pandemic. Prepandemic weight regain rate was risk factor for increased fasting blood glucose. Two years after the pandemic onset, the study participants exhibited increased rates of weight regain, reduced excess weight loss, and an increase in fasting blood glucose and glycosylated hemoglobin parameters.
Material comprises fibres esp. of W, Mo, Ta, Ti, metal oxide, carbide nitride, boride or of a metalloid such as C, B, etc., in a matrix of ceramic material, esp. pure Al2O3 or dental porcelain (K2O, Al2O3. 6SiO2). Esp. for hip joints but also suitable for dental protheses, bridges, and also esp. for tools for making plates corners and other prosthetic joints. The fibres improve the resistance to bending and fracture of the prostheses without affecting the biological passivity, the corrosion resistance or the compressive strength adversely. Use for tools avoids introduction of metal particles into threaded holes, meshes, etc. to cause harmful effects on the patient.
A method for providing medical information including receiving a notification from a medical employee that a medical situation has occurred. The notification is received at a user system. A request is received at the user system from the medical employee for medical data about a patient involved in the medical situation. The medical data is located in a database. It is determined if the patient has consented to the release of the medical data to the medical employee. The determining is initiated by the user system and includes searching the database for a consent form associated with the patient. Medical data is retrieved if the patient has consented to the release of the medical data to the medical employee. The retrieving is initiated by the user system. In response to the retrieving, the medical data is communicated to the medical employee via the user system.
BACKGROUND: Our study presents a single-center experience of resection of intradural spinal tumors either with or without using intraoperative computed tomography-based registration and microscope-based augmented reality (AR). Microscope-based AR was recently described for improved orientation in the operative field in spine surgery, using superimposed images of segmented structures of interest in a two-dimensional or three-dimensional mode.
METHODS: All patients who underwent surgery for resection of intradural spinal tumors at our department were retrospectively included in the study. Clinical outcomes in terms of postoperative neurologic deficits and complications were evaluated, as well as neuroradiologic outcomes for tumor remnants and recurrence.
RESULTS: 112 patients (57 female, 55 male; median age 55.8 ± 17.8 years) who underwent 120 surgeries for resection of intradural spinal tumors with the use of intraoperative neuromonitoring were included in the study, with a median follow-up of 39 ± 34.4 months. Nine patients died during the follow-up for reasons unrelated to surgery. The most common tumors were meningioma (n = 41), schwannoma (n = 37), myopapillary ependymomas (n = 12), ependymomas (n = 10), and others (20). Tumors were in the thoracic spine (n = 46), lumbar spine (n = 39), cervical spine (n = 32), lumbosacral spine (n = 1), thoracic and lumbar spine (n = 1), and 1 tumor in the cervical, thoracic, and lumbar spine. Four biopsies were performed, 10 partial resections, 13 subtotal resections, and 93 gross total resections. Laminectomy was the common approach. In 79 cases, patients experienced neurologic deficits before surgery, with ataxia and paraparesis as the most common ones. After surgery, 67 patients were unchanged, 49 improved and 4 worsened. Operative time, extent of resection, clinical outcome, and complication rate did not differ between the AR and non-AR groups. However, the use of AR improved orientation in the operative field by identification of important neurovascular structures.
CONCLUSIONS: High rates of gross total resection with favorable neurologic outcomes in most patients as well as low recurrence rates with comparable complication rates were noted in our single-center experience. AR improved intraoperative orientation and increased surgeons' comfort by enabling early identification of important anatomic structures; however, clinical and radiologic outcomes did not differ, when AR was not used.
The clinical assessment of patients with disorders of consciousness (DoC) relies on the observation of behavioural responses to standardised sensory stimulation. However, several medical comorbidities may directly impair the production of reproducible and appropriate responses, thus reducing the sensitivity of behaviour-based diagnoses. One such comorbidity is akinetic mutism (AM), a rare neurological syndrome characterised by the inability to initiate volitional motor responses, sometimes associated with clinical presentations that overlap with those of DoC. In this paper, we describe the case of a patient with large bilateral mesial frontal lesions, showing prolonged behavioural unresponsiveness and severe disorganisation of electroencephalographic (EEG) background, compatible with a vegetative state/unresponsive wakefulness syndrome (VS/UWS). By applying an unprecedented multimodal battery of advanced imaging and electrophysiology-based techniques (AIE) encompassing spontaneous EEG, evoked potentials, event-related potentials, transcranial magnetic stimulation combined with EEG and structural and functional MRI, we provide the following: (i) a demonstration of the preservation of consciousness despite unresponsiveness in the context of AM, (ii) a plausible neurophysiological explanation for behavioural unresponsiveness and its subsequent recovery during rehabilitation stay and (iii) novel insights into the relationships between DoC, AM and parkinsonism. The present case offers proof-of-principle evidence supporting the clinical utility of a multimodal hierarchical workflow that combines AIEs to detect covert signs of consciousness in unresponsive patients.
Alzheimer's disease (AD) is a progressive brain disorder marked by abnormal protein accumulation and resulting proteotoxicity. This study examines Chaperone-Mediated Autophagy (CMA), particularly substrate translocation into lysosomes, in AD. The study observes: (1) Increased substrate translocation activity into lysosomes, vital for CMA, aligns with AD progression, highlighted by gene upregulation and more efficient substrate delivery. (2) This CMA phase strongly correlates with AD's clinical symptoms; more proteotoxicity links to worse dementia, underscoring the need for active degradation. (3) Proteins like GFAP and LAMP2A, when upregulated, almost certainly indicate AD risk, marking this process as a significant AD biomarker. Based on these observations, this study proposes the following hypothesis: As AD progresses, the aggregation of pathogenic proteins increases, the process of substrate entry into lysosomes via CMA becomes active. The genes associated with this process exhibit heightened sensitivity to AD. This conclusion stems from an analysis of over 10,000 genes and 363 patients using two AI methodologies. These methodologies were instrumental in identifying genes highly sensitive to AD and in mapping the molecular networks that respond to the disease, thereby highlighting the significance of this critical phase of CMA.